Sargent Investment Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Sargent Investment Group’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,465	Closed	-$210K	–	245
2024 Q4	$210K	Sell	4,465 -3,628	-45%	-$165K	0.03%	219
2024 Q3	$266K	Hold	8,093	–	–	0.05%	179
2024 Q2	$220K	Sell	8,093 -147	-2%	-$4.94K	0.04%	198
2024 Q1	$300K	Sell	8,240 -2,877	-26%	-$84.6K	0.07%	159
2023 Q4	$225K	Buy	+11,117	New	+$186K	0.05%	188
2023 Q3	–	Sell	-10,045	Closed	-$182K	–	215
2023 Q2	$182K	Sell	10,045 -534	-5%	-$8.49K	0.04%	187
2023 Q1	$133K	Buy	10,579 +221	+2%	+$3.23K	0.04%	189
2022 Q4	$152K	Sell	10,358 -500	-5%	-$8.27K	0.05%	181
2022 Q3	$187K	Buy	+10,858	New	+$172K	0.06%	168

Other funds holding TARS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Sargent Investment Group's TARS Position: Q1 2025 in Review

Sargent Investment Group sold out of Tarsus Pharmaceuticals (TARS) in Q1 2025, closing a stake of 4,465 shares — an estimated $210K sold.

Sargent Investment Group first reported a position in TARS in Q3 2022 and held it in 9 quarters. The position peaked at $300K in Q1 2024. 194 funds tracked by Wall St. Rank hold TARS as of Q1 2025.

Sargent Investment Group reported no remaining Tarsus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Sargent Investment Group sold 4,465 Tarsus Pharmaceuticals shares in Q1 2025, an estimated $210K.
Sargent Investment Group first reported a position in Tarsus Pharmaceuticals in Q3 2022 and held it in 9 quarters.
Sargent Investment Group's Tarsus Pharmaceuticals position peaked at $300K in Q1 2024.
194 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2025.

Based on Sargent Investment Group's 13F filing for Q1 2025, filed 5 May 2025.